Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors


NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) — Renalytix Plc (NASDAQ:RNLX) (LSE: RENX) today announced that, following the Company's announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix.  

As an accomplished leader in healthcare innovation, Mr. Scannell brings more than 30 years of experience in medical technology to the Renalytix Board, and previously served as President and C.O.O. of Stryker. Mr. Scannell currently serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Collagen Matrix. He holds Bachelor of Business Administration and Master of Business Administration degrees from the University of Notre Dame.

For further information, please contact:

Renalytix plc  
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore  
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams  
Walbrook PR Limited Tel: 020 7933 8780 or
Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893 / 07584 391 303 / 07407 804 654  
CapComm Partners Tel: 415-389-6400 or
Peter DeNardo  

AIM Rule Regulatory Disclosures
In accordance with Schedule 2(g) of the AIM Rules, Timothy (Tim) John Scannell (aged 57) holds or has held in the past 5 years the following directorships and partnerships:

Current Past 5 years
Insulet Corporation Berchtold Corporation
Novocure Inc. CerSys Inc.
Collagen Matrix, Inc. Charger Holding Corp.
Gilmartin Fund I L.P. Concentric Medical, Inc.
  Entellus Intermediate Sub, Inc.
  Everest Biomedical Instruments Company
  Explorer Merger Sub Corp.
  Fulcrom, Corp.
  HeartSine Technologies, LLC
  Hit Acquisition Corporation
  Hygia Health Services, Inc.
  Image Guided Technologies, Inc.
  Infinity MSD Corp.
  Infinity …

Full story available on


Please enter your comment!
Please enter your name here